Singh Mukesh, Arora Rohit
Department of Cardiology, Chicago Medical School, Rosalind Franklin University of Medicine and Sciences, North Chicago, IL.
Am J Ther. 2016 Nov/Dec;23(6):e1842-e1856. doi: 10.1097/MJT.0000000000000187.
Ischemic heart disease remains a major public health problem nationally and internationally. Stable ischemic heart disease (SIHD) is one of the clinical manifestations of ischemic heart disease and is generally characterized by episodes of reversible myocardial demand/supply mismatch, related to ischemia or hypoxia, which are usually inducible by exercise, emotion, or other stress and reproducible-but which may also be occurring spontaneously. Improvements in the treatment of acute coronary syndromes along with increasing prevalence of cardiovascular risk factors, including diabetes and obesity, have led to increasing population of patients with SIHD. A significant number of these continue to have severe angina despite medical management and revascularization procedures performed and may progress to refractory angina. This article reviews the newer therapies in the treatment of SIHD with special focus in treating patients with refractory angina.
缺血性心脏病在国内和国际上仍然是一个重大的公共卫生问题。稳定型缺血性心脏病（SIHD）是缺血性心脏病的临床表现之一，其一般特征为与缺血或缺氧相关的可逆性心肌供需不匹配发作，通常由运动、情绪或其他应激诱发且可再现——但也可能自发发生。急性冠状动脉综合征治疗方法的改进以及包括糖尿病和肥胖在内的心血管危险因素患病率的上升，导致SIHD患者数量不断增加。尽管进行了药物治疗和血运重建手术，但这些患者中有相当一部分仍有严重心绞痛，且可能进展为顽固性心绞痛。本文综述了SIHD治疗的新疗法，特别关注顽固性心绞痛患者的治疗。
